エージェントは治療用抗体を信頼性高く設計できるか
Can agents reliably design therapeutic antibodies?
LLMエージェントによる抗体設計を指示追従型とブラックボックス型で評価し、ツールや設計履歴の影響を分析した研究。
詳しい要約
1. どんなもの?
2. 先行研究と比べてどこがすごい?
3. 技術・手法の肝は?
4. どうやって有効だと検証した?
5. 議論はある?
6. 次に読むべき論文は?
※ AIが要旨から生成した要約です。正確性は原文をご確認ください。
著者: Asli Alpman, Nick Bhattacharya, Aaron Solomon, Hunter Elliott
分類: q-bio.QM, cs.LG
原文アブストラクト
Recent work has demonstrated agents driving protein design workflows, either through orchestration of specialized tools or direct manipulation of sequences. Yet the fidelity with which agents follow protein design instructions and the factors contributing to their effectiveness remain understudied. We examine agentic antibody design under two settings: when explicit molecular-editing instructions are provided and when agents receive only previously-scored sequences and are prompted to propose improvements. We call the first task-guided and the second black-box design. For the task-guided setting, we curate ten expert-validated affinity-improvement tasks and show that LLM judges closely reproduce programmatic evaluations of instruction following. We then study two augmentations: access to antibody-relevant tools and to previously scored design history. Tools improve instruction following (IF) and sequence space exploration while reducing optimization performance, whereas design history reduces IF but improves optimization performance at the expense of exploration. Finally, we combine taskguided and black-box design within an in silico optimization loop and show that our agentic optimizer performs comparably to an established Bayesian optimization baseline.